Spike apc

Manufactured by Thermo Fisher Scientific

Spike-APC is a lab equipment product designed to detect the presence of the SARS-CoV-2 spike protein. It utilizes flow cytometry technology to identify and quantify the spike protein in a sample.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd14 bv510, by BioLegend (2 mentions) Anti cd19 percp cy5, by BioLegend (2 mentions) Anti cd3 apc cy7, by BioLegend (2 mentions) Anti igm pe, by BioLegend (2 mentions) Anti cd8 apc cy7, by BioLegend (2 mentions) Anti igd pacific blue, by BioLegend (2 mentions) Anti igg pecy7, by BD (2 mentions) Spike alexa488, by Thermo Fisher Scientific (2 mentions) First strand superscript 3 buffer, by Thermo Fisher Scientific (2 mentions) Dtt and h2o, by Thermo Fisher Scientific (2 mentions) Facsmelody, by BD (2 mentions) Superscript 3 reverse transcriptase, by Thermo Fisher Scientific (2 mentions) Rnaseout, by Thermo Fisher Scientific (2 mentions)

2 protocols using spike apc

Sorting SARS-CoV-2 Spike-Specific B Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fluorescence-activated cell sorting of cryopreserved PBMCs was performed on a BD FACS Melody. Sorting baits (SARS-CoV-2 Spike) was pre-complexes with the streptavidin flurophore at a 1:4 molar ratio prior to addition to cells. PBMCs were stained with live/dead (fixable Aqua Dead, Thermofisher), anti-CD3-APC/Cy7 (Biolegend), anti-CD8-APC-Cy7 (Biolegend), anti-CD14-BV510 (Biolegend), anti-CD19-PerCP-Cy5.5 (Biolegend), anti-IgM-PE (Biolegend), anti-IgD-Pacific Blue (Biolegend) and anti-IgG-PeCy7 (BD) and Spike-Alexa488 (Thermofisher Scientific, S32354) and Spike-APC (Thermofisher Scientific, S32362). Live CD3/CD8⁻CD14⁻CD19⁺IgM⁻IgD⁻IgG⁺Spike⁺Spike⁺ cells were sorted into individual wells containing RNase OUT (Invitrogen), First Strand SuperScript III buffer, DTT and H₂O (Invitrogen) and RNA was converted into cDNA (SuperScript III Reverse Transcriptase, Invitrogen) using random hexamers following the manufacturer’s protocol.

Graham C., Seow J., Huettner I., Khan H., Kouphou N., Acors S., Winstone H., Pickering S., Galao R.P., Lista M.J., Jimenez-Guardeno J.M., Laing A.G., Wu Y., Joseph M., Muir L., Ng W.M., Duyvesteyn H.M., Zhao Y., Bowden T.A., Shankar-Hari M., Rosa A., Cherepanov P., McCoy L.E., Hayday A.C., Neil S.J., Malim M.H, & Doores K.J. (2021). Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike. bioRxiv.

+ Open protocol

+ Expand

SARS-CoV-2 Antigen-Specific B Cell Sorting

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fluorescence-activated cell sorting of cryopreserved PBMCs was performed on a BD FACS Melody as previously described (Graham et al., 2021 (link)). Sorting baits (SARS-CoV-2 Spike and RBD) was pre-complexed with the streptavidin fluorophore at a 1:4 molar ratio prior to addition to cells. PBMCs were stained with live/dead (fixable Aqua Dead, Thermofisher), anti-CD3-APC/Cy7 (Biolegend), anti-CD8-APC-Cy7 (Biolegend), anti-CD14-BV510 (Biolegend), anti-CD19-PerCP-Cy5.5 (Biolegend), anti-IgM-PE (Biolegend), anti-IgD-Pacific Blue (Biolegend) and anti-IgG-PeCy7 (BD) and Spike-Alexa488 (Thermofisher Scientific, S32354) and Spike-APC (Thermofisher Scientific, S32362) or RBD-Alexa488 and RBD-APC. Live CD3/CD8^-CD14^-CD19⁺IgM^-IgD^-IgG⁺Spike⁺Spike⁺ or CD3/CD8^-CD14^-CD19⁺IgM^-IgD^-IgG⁺RBD⁺RBD⁺ cells were sorted using a BD FACS Melody into individual wells containing RNase OUT (Invitrogen), First Strand SuperScript III buffer, DTT and H₂O (Invitrogen) and RNA was converted into cDNA (SuperScript III Reverse Transcriptase, Invitrogen) using random hexamers (Bioline Reagents Ltd) following the manufacturer’s protocol.

Seow J., Graham C., Hallett S.R., Lechmere T., Maguire T.J., Huettner I., Cox D., Khan H., Pickering S., Roberts R., Waters A., Ward C.C., Mant C., Pitcher M.J., Spencer J., Fox J., Malim M.H, & Doores K.J. (2022). ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. Cell Reports, 39(5), 110757.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!